ClinicalTrials.gg
TerminatedNCT05010850SAFE-2Updated Jul 3, 2025Results posted

SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

An interventional study of Colovac and Stoma Creation in Colorectal Cancer, Rectal Cancer and Rectal Tumor, sponsored by SafeHeal Inc. Terminated at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Primary conditionRectal NeoplasmsRegistry: Colorectal NeoplasmsReclassifiedWhy we changed it
Registry
Colorectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Rectal Neoplasms
Why
  1. The study's listed conditions name Rectal Neoplasms, a narrower term within Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by SafeHeal Inc · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Voluntary and temporary suspension of enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 781 studies in Rectal Neoplasms with a site in United States — 80 open to participants now, 141 under way, 9 of them phase 3. Rectal Neoplasms · United States.

Enrollment
457th of 620
18 · median 39
Started
2022
with 32 others
No phase
149 of 781
24 open now
Registered
677th of 781
by date

Among the 781 studies in Rectal Neoplasms with a site in United States, this one is the 457th largest by enrollment of the 620 interventional ones that give a count, is one of 33 that started in 2022, is one of 149 with no phase, and was the 677th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

80 of the 781 studies in Rectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

75 more — sign in →

All 80 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 781 studies in Rectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A randomized trial to assess the safety and effectiveness of the Colovac in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer.

Read the detailed description

A primary diverting stoma is widely used by surgeons in order to bypass the low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Typically, a stoma is created for all high-risk patients which means that many patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit.

Colovac is a local, temporary, minimally invasive bypass device that provides protection of the anastomosis and safely postpones stoma creation for 10 days after surgery. By postponing stoma creation for 10 days, Colovac is designed to avoid stoma creation in all patients except those patients whose anastomoses have not healed by 10 days after surgery, allowing the others to return to normal activity more quickly and safely.

03

Conditions studied

  • Colorectal Cancer
  • Rectal Cancer
  • Rectal Tumor
  • Rectal/Anal

Browse trials for

Keywords

  • anastomosis
  • leak
  • colorectal
  • ileostomy
04

In context

Rectal Neoplasms Reclassified

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

This study's enrollment of 18 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

SafeHeal Inc is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Rectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (greater than 18 years of age)
  2. Eligible to undergo open or minimally invasive sphincter-preserving lower anterior resection (anastomosis within 10 cm of the anal verge) with planned diverting loop ileostomy for malignant indication, assessed by a multi-disciplinary team.
  3. (ECOG) Performance Status ≤ 2
  4. Willing to comply with protocol-specific treatment and study visits and to sign a written Form

Exclusion criteria

Exclusion Criteria:

  1. History of left colitis
  2. Known allergy to nickel or other components of the Colovac kit
  3. Pregnant or nursing female subject
  4. Concomitant major surgical procedure in combination with Colorectal resection (e.g.. hepatectomy)
  5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol described procedures or interfere with the interpretation of study results. including, but not limited to:

    1. COVID-19 positive (active infection) if test required by hospital
    2. Immunodeficiency ( \< 500 mm3)
    3. Systemic therapy within the past 6 months
    4. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery
    5. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
    6. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis
    7. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging
    8. Severe Malnutrition defined as ≥ 10% weight loss within 3 months prior to enrollment
    9. Stage IV colorectal cancer unless curative intent R0 resection is planned AND there is no associated peritoneal disease
  6. The subject is currently participating in another drug or device study
  7. Occurrence of any of the following during the colorectal surgery:

    1. Blood loss (>750 cc)
    2. Blood transfusion
    3. Any new sign of ischemia
    4. Positive air leak test
    5. Inadequate bowel preparation
    6. Anastomosis location greater than 10 cm from the anal verge
    7. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Colovac

    Patients receive Colovac during colorectal surgery

    Device: Colovac

  • Active comparator
    Standard of Care

    Patients receive the standard of care, a protective stoma, during colorectal surgery

    Procedure: Stoma Creation

Interventions

  • DeviceColovac

    A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)

  • ProcedureStoma Creation

    Protective ileostomy

07

What researchers measure

Primary outcomes

  1. Avoidance of Ostomy

    Reduction in stoma creation rate

    Time frame: 12 Months

  2. Safety Major Complications

    Rate of subjects with major complications

    Time frame: 12 Months

08

Results

Posted Jul 3, 2025
Limitations and caveats
The SAFE-2 study was voluntarily terminated early by the sponsor due to non-safety reasons. Given the limited sample size of SAFE-2, further studies with larger cohorts are recommended.

Participant flow

Participant flow — Overall Study
MilestoneColovacStandard of Care
Started108
Completed86
Not completed22

Outcome measures

PrimaryAvoidance of Ostomy

Reduction in stoma creation rate

Time frame:
12 Months
Reported as:
Count of participants · Participants
Avoidance of Ostomy
ParticipantsColovacStandard of Care
Avoidance of Ostomy70
PrimarySafety Major Complications

Rate of subjects with major complications

Time frame:
12 Months
Reported as:
Count of participants · Participants
Safety Major Complications
ParticipantsColovacStandard of Care
Safety Major Complications32

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care1/8 (12.5%)7/8 (87.5%)6/8 (75%)
Colovac0/10 (0%)6/10 (60%)7/10 (70%)
Most frequent serious events
Most frequent serious events
EventStandard of CareColovac
Anastomosis LeakageGeneral disorders2/84/10
General state of deterioration with dehydration, resulting in deathGeneral disorders1/80/10
Undernutrition with Naso Gastric TubeGastrointestinal disorders1/80/10
IleusGastrointestinal disorders1/80/10
InfectionInfections and infestations1/80/10
Urinary Tract InfectionInfections and infestations1/80/10
CRP ElevationInfections and infestations1/80/10
Dehydration which resolvedGeneral disorders1/80/10
Colon IntussusceptionGastrointestinal disorders0/81/10
Acute Renal FailureRenal and urinary disorders0/81/10
Most frequent other events
Showing 10 of 21
Most frequent other events
EventStandard of CareColovac
Nausea/vomitingGastrointestinal disorders1/82/10
Abdominal/ Anal painGastrointestinal disorders1/81/10
CholestasisGastrointestinal disorders1/80/10
DiarrheaGastrointestinal disorders1/81/10
DyspneaRespiratory, thoracic and mediastinal disorders1/80/10
Heart FailureCardiac disorders1/80/10
IleusGastrointestinal disorders1/81/10
Infection of incision/surgery wound on left sideSurgical and medical procedures1/80/10
Other - Epigastric PainGastrointestinal disorders1/80/10
Other - Lymphopenia to XelodaBlood and lymphatic system disorders1/80/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)ColovacStandard of CareTotal
Mean67.1 ± 10.960.9 ± 11.464.3 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)ColovacStandard of CareTotal
Female639
Male459
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ColovacStandard of CareTotal
Count of participants——0
Mean Body Mass Index
Mean Body Mass Index(kg/m^2)ColovacStandard of CareTotal
Mean24.8 ± 5.525.7 ± 4.825.2 ± 5.1
09

Study locations

16 sites
  • Kaiser Permanente - Los Angeles
    Los Angeles, California 90027, United States
  • USC Keck Hospital
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01605, United States
  • Dartmouth-Hitchcock
    Lebanon, New Hampshire 03756, United States
  • Maimonides Medical Center
    Brooklyn, New York 11219, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Lenox Hill Hospital
    New York, New York 10075, United States
  • Lankenau Medical Center
    Wynnewood, Pennsylvania 19096, United States
  • Universitair Ziekenhuis Antwerpen
    Edegem, Antwerp 2650, Belgium
  • CHU de Besancon
    Besançon, 25030, France
  • ICM Val d'Aurelle
    Montpellier, 34090, France
  • Hopital Saint-Louis
    Paris, 75010, France
  • CHU Rouen Normandie
    Rouen, 76031, France
  • Hôpital Saint Antoine Paris
    Paris, Île-de-France Region 75571, France
10

References and documents

Publications

  • Hain E, Lefevre JH, Ricardo A, Lee S, Zaghiyan K, McLemore E, Sherwinter D, Rhee R, Wilson M, Martz J, Maykel J, Marks J, Marcet J, Rouanet P, Maggiori L, Komen N, De Hous N, Lakkis Z, Tuech JJ, Attiyeh F, Cotte E, Sylla P. SafeHeal Colovac Colorectal Anastomosis Protection Device evaluation (SAFE-2) pivotal study: an international randomized controlled study to evaluate the safety and effectiveness of the Colovac Colorectal Anastomosis Protection Device. Colorectal Dis. 2024 Jun;26(6):1271-1284. doi: 10.1111/codi.17012. Epub 2024 May 15. PubMed 38750621 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jan 2024, 24 months.

Results were first posted in Jul 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2021
First posted
Aug 18, 2021
StartActual
Jan 17, 2022
Primary completionActual
Jan 19, 2024
CompletionActual
Jan 19, 2024
Results first posted
Jul 3, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05010850
Lead sponsor
SafeHeal Inc
Responsible party
Sponsor
First posted
Aug 18, 2021
Start date
Jan 17, 2022
Primary completion
Jan 19, 2024
Completion
Jan 19, 2024
Results posted
Jul 3, 2025
Last update
Jul 3, 2025

Study contacts

Patricia Sylla, MD
principal investigator · MOUNT SINAI HOSPITAL
Jeremie Lefevre, MD, PhD
principal investigator · Hopital Saint Antoine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion